InsightRX Achieves 96.1 Performance Score in KLAS Spotlight as the First Precision Dosing AI Solution
SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Impact (KLAS Spotlight 2025) -- InsightRX, a leader in model-informed precision dosing (MIPD) software, announced today that it is the first pharmacy-focused precision dosing solution recognized in the 2025 KLAS Emerging Company Spotlight report. With an overall performance score of 96.1, placing it among the highest-rated vendors in clinical decision support, InsightRX was highlighted for its ability to improve clinician experience, support seamless EHR integration, and deliver measurable patient outcomes.
KLAS independently surveyed InsightRX customers and reported:
Overall performance score: 96.1 (vs. Best in KLAS average of 80.6%)
Key categories:
- Supports integration goals: A+
- Product has needed functionality: A-
- Executive involvement: A+
- Likely to recommend: A+
Customer loyalty:
- 100% would buy again
- 100% include InsightRX in long-term plans
Outcomes delivered:
- Decreased medication side effects
- Higher therapeutic target attainment
- Reduction in acute kidney injury
- Outcomes achieved within 6 months of adoption
What Pharmacy Leaders Are Saying
"The system dropped our rate of kidney injury for patients on certain antibiotics. Our estimate is that the system ultimately saves us hundreds of thousands of dollars a year." –Manager
"The integration with the EHR is InsightRx's strength. We get real-time, immediate dosing recommendations." –Manager
Beyond The Spotlight: Next Generation Clinical Decision Support
While the KLAS report validated InsightRX for its leadership in precision dosing and clinical decision support today, the company is already expanding its platform to reach new drug classes and therapeutic areas. A KLAS score of 96.1 is immediately relevant for hospitals managing high-risk therapies now, but the underlying platform is designed to extend far beyond current use cases.
The next horizon is a future powered by InsightRX's upcoming agentic AI system. This next generation clinical decision support tool will bring together PK/PD modeling and simulation with broader sources of clinical context, including guidelines, institutional protocols, and pharmacogenomics. By collating and reasoning across these inputs, this new platform will generate actionable insights that help optimize stewardship programs, advance antimicrobial use, and integrate genomic data into routine care.
"We are honored to be recognized by KLAS with one of the highest scores in the clinical decision support category. Their reputation is unmatched, and this validation reflects the measurable impact our platform is already having in precision dosing," said Dr. Sirj Goswami, PhD, CEO and Co-Founder of InsightRX. "Our vision is to expand precision dosing to new drug classes and therapeutic areas, while building the foundation for the next generation of clinical decision support. We're currently working to combine the proven science of PK/PD modeling with agentic AI to create smarter, more connected systems that will transform pharmacy workflows and patient care across complex therapeutic domains."
Media Contact:
Dr. Nikhil Bilkha
Marketing Director
nikhil@insight-rx.com
InsightRX is a healthcare technology company providing a cloud-based precision dosing platform that combines pharmacokinetic models, real-world data, and machine learning to help clinicians individualize therapy. Their software is used by leading hospitals and IDNs to support data-driven dosing decisions across critical therapeutics areas, including infectious diseases, bone marrow transplant, anticoagulation, anticonvulsants, and more. Learn more at www.insight-rx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insightrx-achieves-96-1-performance-score-in-klas-spotlight-as-the-first-precision-dosing-ai-solution-302576507.html
SOURCE InsightRX